Press Release

The Health Innovations Conference will create opportunities to initiate collaborative efforts in Health Innovation with representatives from the National Institute of Allergy and Infectious Diseases (NIAID), Clarke Group, CryptoSavannah, Case Hospital, Centers for Diseases Control and Prevention (CDC), United States Agency for International Development (USAID), Andela Uganda and Janssen, the Pharmaceutical Companies of Johnson and Johnson.

Researchers from IDI are part of a prestigious consortium to define the best and safest treatments for patients who require treatment for tuberculosis (TB) whilst receiving second-line antiretroviral therapy (ART) led by the University of Liverpool, the VirTUAL Consortium (Vulnerable patient Tuberculosis AntiretroviraL) is funded by the European and Developing Countries Clinical Trials Partnership (EDCTP) as part of EDCTP2 – an international initiative to optimize the safe and effective treatments of poverty related diseases including HIV and TB.